Abstract. For testing one{sided but also two{sided hypotheses concerning several treatment arms in group sequentially performed clinical trials with arbitrary outcome variables, a general learning method is considered that allows for a complete self{designing of the study. All information available prior to a stage is used for estimating the sample size and the weight for the next step. In 'using up' the variance, the test statistic is built in a bounded nite but random number of stages to test just once the null{hypothesis on rejecting.
Introduction
In a recent paper L. Fisher 1] introduces in a general setting for normal variables with known variances self{designing trials, for which Shen and L. Fisher 2] with regard to a one{sided hypothesis give a concrete proposal for building the test statistic. There the sequence of sample sizes is xed prior to the beginning of the study, although in 1] there is already pointed out that this can be chosen adaptively using information prior to the respective stage. One continues to assign groups of subjects until the variance of the test statistic is 'used up'. Related In the present paper we employ the inverse normal transformation of the p{values suiting so under the null{hypothesis to the assumptions of L. Fisher's 1] main result. In 14] this p{value transformation is taken in connection with the classical group sequential trials. By a reformulation of the original hypothesis also two{sided cases can be considered for arbitrary response variables in several treatment arms.
A general learning rule for completely self{designing trials is presented below which at each stage adaptively estimates the sample size and the weight associated to that stage upon all prior data knowledge. 2 The basic procedure for instance with the known homogeneity tests. In the case of I = 2 and e.g. i = 1: verum, i = 2: placebo, for a one{sided comparison one puts = # 1 ?# 2 . Note that in the general formulation here # i may represent a probability if the trial deals with binary variables. The study is formally divided into an in nite number of disjoint study parts: stp(1), : : : , stp(k), : : : , and it is the aim of a designing rule, that of those only a nite number, say K, has to be carried out really. In stp(k) n k patients are randomized across the I treatment groups, each consisting so of n ik patients, For a quantity a to be used in or for stp(k) let us introduce the notation a =âfk ? 1g; i. e. a =âfstp(0), stp(1), : : : , stp(k ? 1)g; to indicate that a is determined or estimated upon all the knowledge obtained in the previous study parts before the beginning of stp(k), where stp(0) may denote the prior information, implyingâf0g to be in any case a constant in the present trial.
De ning now an in nite sequence of nonnegative weights w 1 ; : : : ; w k ; : : : , such that with probability one under H 0 there exists a nite (random) K with we set the control parameters weight w k and sample size n k for stp(k) as follows:
w k = A generally longer running sequence of study parts we obtain if in the formula for W(k) we replace the second factor by patients, to be equally randomized, as in the following stages, too, across the two treatment groups, and the weight w 2 1 = 40=200 = 0:2. The other chosen control parameters can be seen in the rule the parameter estimates remained as expected and so the next stage can get the rest of possible weight.
Secondly we see that we have not much payed for the learning in form of the number of patients to be enclosed: in a xed sample size plan we would have calculated, with the same approximate formula, 292 necessary patients, only 10 less than above, if the parameter di erence would have been known in advance. So we can get the impression that our learning algorithm is on the one hand cautious in spending high weights too early, and on the other hand it uses patients sparingly.
